Sanofi's Cenrifki Approved in EU for Non-Relapsing SPMS

The European Commission has approved Sanofi's Cenrifki (tolebrutinib) for treating secondary progressive multiple sclerosis (SPMS) without relapses. This approval marks a significant advancement, offering a new therapeutic option for patients with SPMS by targeting disability progression.

Cenrifki's approval is based on positive results from the HERCULES phase 3 study, focusing on non-relapsing SPMS, along with supporting data from GEMINI 1 and 2 studies in relapsing multiple sclerosis. The studies indicate that Cenrifki significantly delays disability progression onset.

The safety profile is consistent, noting liver injury as a risk, necessitating strict liver monitoring. Despite risks, Cenrifki's approval signifies Sanofi's dedication to innovative solutions in neurology, enhancing treatment landscapes for neuro-inflammatory conditions.